Skip to content
Generic & Biosimilar Entry

Generic Competition Analysis

Anticipate generic entry — and defend.

A defensible framework for analyzing generic competition — entrant pace, price erosion, channel dynamics and defender plays.

Decision angle

"How will generic competition reshape this molecule’s economics — and what defense works?"

TL;DR

Generic erosion follows predictable curves shaped by number of entrants, AG presence, channel structure and reference-pricing rules.

Generic competition follows predictable patterns. Live tracking of ANDAs, AG launches and erosion curves powers both defender and challenger strategy.

Key insights

What we’re seeing in the data.

01

Entrant count drives erosion pace

3+ generics within 6 months erodes price 80–90%.

02

AG slows erosion

Authorized generic captures meaningful share.

03

Channel structure matters

GPO, mail-order, retail dynamics differ.

80–90%
Price erosion
3+ entrants
AG
Defender lever
Effective
4
Driver axes
Tracked
Geo
Variance
Material
Decision framework

How to think about it.

  1. 01

    Forecast entrants

    ANDA filings, manufacturing capacity.

  2. 02

    Project erosion

    Curve from comparable molecules.

  3. 03

    Model defender response

    AG, contracting, lifecycle.

  4. 04

    Track in real-time

    Sales + share dashboards.

Considerations

What separates a good answer from a defensible one.

Settlements

Pay-for-delay etc.

Manufacturing capacity

Limits entry pace.

Quality issues

Recalls reset competition.

Sources & tools

Where the signal comes from.

FDA Orange Book IQVIA generic data Cortellis IP Channel data (DTP/retail)
FAQ

Common questions.

How fast is typical erosion?

80–90% in 12 months with 3+ entrants.

Best defender play?

AG combined with formulation lifecycle.

Want this answered on your data?

We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.

Talk to a strategist